Clinical trials: Glioblastoma
Glioblastoma Multiforme
A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma
This open-label, multicenter study will evaluate the safety and efficacy of RO5323441 in combination with Avastin (bevacizumab) in patients with recurrent glioblastoma.
- Trial name
- NCT01308684
- Testing
- RO5323441 + bevacizumab [Avastin], bevacizumab [Avastin]
- Where
- 4 sites in Denmark, France and 2 more
- Volunteers
- 22 people
- Sponsor
- Hoffmann-La Roche
Glioblastoma Multiforme, GBM
Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma
The primary objective of this study is to determine the 6-month Progression free survival (PFS) when intravenous (IV) AR-67 is administered in adults with confirmed recurrence of GBM who have not recently (> 90 days) recurred…
- Conditions
- Glioblastoma Multiforme, GBM, Gliosarcoma
- Trial name
- NCT01124539
- Testing
- AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)
- Where
- 9 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Arno Therapeutics
Glioblastoma
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
This clinical study will assess the doses of BKM120 appropriate for patients with newly diagnosed glioblastoma when given in combination with radiotherapy and temozolomide.
- Trial name
- NCT01473901
- Testing
- BKM120 + temozolomide, BKM120 +temozolomide with/without radiotherapy
- Where
- 8 sites in United States, Australia and 2 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma
Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma
The phase I portion of study is designed to determine the Maximum Tolerated Dose (MTD) of BSI-201 with two clinically relevant dosing regimens of temozolomide (TMZ).
- Trial name
- NCT00687765
- Testing
- bsi-201 plus temozolomide
- Where
- 8 sites in United States
- Volunteers
- 126 people
- Sponsor
- Sanofi
Carcinoma, Renal Cell, Glioblastoma
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment while the majority of patients will eventually…
- Conditions
- Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular
- Trial name
- NCT01441388
- Testing
- Crizotinib plus VEGF inhibitor combinations, Crizotinib plus axitinib, Crizotinib plus sunitinib
- Sponsor
- Pfizer
Glioblastoma Multiforme
Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme
This is an open-label, dose finding, multiple-dose study in subjects with recurring/relapsing glioblastoma multiforme. Three dose levels of MPC-6827 will be administered with carboplatin to three separate cohorts.
- Trial name
- NCT00635557
- Testing
- MPC-6827 + Carboplatin
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Myrexis Inc.
Glioblastoma
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
The primary objective of this trial is to determine the optimal dose and imaging time point(s) of I-124-CLR1404 in subjects with newly diagnosed and recurrent glioma to be used in future trials.
- Trial name
- NCT01898273
- Testing
- I-124-CLR1404
- Where
- 9 sites in United States
- Volunteers
- 7 people
- Sponsor
- Cellectar Biosciences, Inc.
Glioblastoma Multiforme
Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme
The objective of this study is to assess the efficacy and safety of TLN-4601 used to treat patients with Glioblastoma Multiforme(GBM) that recur/progress after receiving first line systemic therapy post surgery/radiotherapy.
- Trial name
- NCT00730262
- Testing
- TLN-4601
- Where
- 8 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Thallion Pharmaceuticals
Solid Tumors
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with…
- Trial name
- NCT02711137
- Testing
- INCB057643, Gemcitabine, Paclitaxel
- Where
- 18 sites in United States, Belgium and 1 more
- Volunteers
- 137 people
- Sponsor
- Incyte Corporation
Malignant Glioma
Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
This study is designed to evaluate the clinical activity of CDX-110 vaccination when given with standard of care treatment (maintenance temozolomide therapy).
- Trial name
- ACT III (NCT00458601)
- Testing
- CDX-110 with GM-CSF, Temozolomide
- Where
- 34 sites in United States
- Volunteers
- 82 people
- Sponsor
- Celldex Therapeutics
Glioblastoma Multiforme
A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme
To evaluate CAN008 safety, tolerability, and pharmacokinetics (PK) of CAN008 when administered concurrent Plus Concomitant Temozolomide During and After Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme.
- Trial name
- NCT02853565
- Testing
- CAN008
- Where
- 2 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- CANbridge Life Sciences Ltd.
Glioblastoma Multiforme, Glioblastoma
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
This will be a prospective, randomized, standard of care (SoC) controlled, parallel, open-label, multicenter pivotal study to investigate the efficacy and safety of Bevacizumab (BEV) in combination with or without microbubble…
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioblastoma Multiforme, Adult, Glioma
- Trial name
- NCT06496971
- Testing
- Bevacizumab, Microbubble, Low-Intensity Focused Ultrasound
- Where
- 2 sites in Taiwan
- Volunteers
- 32 people
- Sponsor
- NaviFUS Corporation
Glioblastoma
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human interleukin-12 (IL-12).
- Trial name
- NCT03636477
- Testing
- Ad-RTS-hIL-12, veledimex, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Alaunos Therapeutics
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
High Grade Glioma
Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma
A Phase 1 Multi-center clinical Trial Evaluating the Safety and Tolerability of 5-aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With recurrent High Grade Glioma…
- Trial name
- NCT05362409
- Testing
- 5 Aminolevulinic Acid, CV01-delivered ultrasound
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Alpheus Medical, Inc.
Glioblastoma
Targeted Survivin DC Cell Injection for the Treatment of GBM
Primary Objective: To evaluate the safety and tolerability of targeted Survivin DC cell injection for postoperative treatment of newly diagnosed primary glioblastoma multiforme.
- Trial name
- NCT06524063
- Testing
- Survivin-loaded dendritic cell injection
- Volunteers
- 9 people
- Sponsor
- Beijing Tricision Biotherapeutics Inc
Glioblastoma
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
The goal of this clinical trial is to evaluate the safety and efficacy of PLB1001 Enteric Capsules in the treatment of PTPRZ1-MET fusion gene positive recurrent secondary glioblastoma. The main questions it aims to answer are: 1.
- Trial name
- NCT06105619
- Testing
- PLB1001, Temozolomide, Cisplatin combined with Etoposide
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Beijing Pearl Biotechnology Limited Liability Company
Recurrent Glioblastoma
TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab
This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy.
- Trial name
- NCT03856099
- Testing
- TTAC-0001
- Where
- 3 sites in United States, Australia
- Volunteers
- 19 people
- Sponsor
- PharmAbcine
Malignant Glioma, Glioblastoma
Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)
A Phase I, open-label, non-randomized, sequential dose escalation cohort trial of the safety, tolerability, and maximum tolerated dose (MTD) of AP23573 when administered intravenously as a 30-minute infusion, once daily for five…
- Conditions
- Malignant Glioma, Glioblastoma, Gliosarcoma
- Trial name
- NCT00087451
- Testing
- AP23573
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Glioblastoma, Adult
Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9
Recurrent glioblastoma (GBM) is a disease with high unmet clinical need. The standard of care for patients with GBM includes surgery, radiotherapy and chemotherapy.
- Trial name
- SC9-GBM-01 (NCT03744026)
- Testing
- SonoCloud-9, Carboplatin
- Where
- 6 sites in United States, France
- Volunteers
- 38 people
- Sponsor
- CarThera